Cargando…

Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD

TAR DNA binding protein 43 (TDP-43) is a DNA/RNA binding protein involved in pivotal cellular functions, especially in RNA metabolism. Hyperphosphorylated and ubiquitinated TDP-43-positive neuronal cytoplasmic inclusions are identified in the brain and spinal cord in most cases of amyotrophic latera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamaki, Yoshitaka, Urushitani, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604209/ https://www.ncbi.nlm.nih.gov/pubmed/36293362 http://dx.doi.org/10.3390/ijms232012508

Ejemplares similares

Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD
por: Wood, Alistair, et al.
Publicado: (2021)

Towards a TDP-43-Based Biomarker for ALS and FTLD
por: Feneberg, Emily, et al.
Publicado: (2018)

The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD
por: Berning, Britt A., et al.
Publicado: (2019)

Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
por: Pickles, Sarah, et al.
Publicado: (2022)

Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS
por: Chang, Cheng-Fu, et al.
Publicado: (2016)

Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD–ALS spectrum disorders
por: Janssens, Jonathan, et al.
Publicado: (2013)

Codon-optimized TDP-43 mediates neurodegeneration in a Drosophila model of ALS/FTLD
por: Yusuff, Tanzeen, et al.
Publicado: (2023)

NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility
por: Gleixner, Amanda M., et al.
Publicado: (2022)

Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD
por: Diaper, Danielle C., et al.
Publicado: (2013)

TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP
por: Arseni, Diana, et al.
Publicado: (2023)

TDP-43 Vasculopathy in the Spinal Cord in Sporadic Amyotrophic Lateral Sclerosis (sALS) and Frontal Cortex in sALS/FTLD-TDP
por: Ferrer, Isidro, et al.
Publicado: (2021)

Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD–TDP subtypes
por: Neumann, Manuela, et al.
Publicado: (2020)

Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
por: Fiondella, Luigi, et al.
Publicado: (2023)

CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS
por: Uchida, Tsukasa, et al.
Publicado: (2016)

mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms
por: Scherz, Barbara, et al.
Publicado: (2018)

Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43
por: Tan, Rachel H, et al.
Publicado: (2013)

Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U
por: Tsai, Kuen-Jer, et al.
Publicado: (2010)

C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation
por: Josephs, Keith A., et al.
Publicado: (2019)

Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD
por: Khosravi, Bahram, et al.
Publicado: (2017)

Lipid alterations in human frontal cortex in ALS‐FTLD‐TDP43 proteinopathy spectrum are partly related to peroxisome impairment
por: Andrés‐Benito, Pol, et al.
Publicado: (2021)

Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies
por: Koga, Shunsuke, et al.
Publicado: (2023)

Pathogenic Mutation of TDP-43 Impairs RNA Processing in a Cell Type-Specific Manner: Implications for the Pathogenesis of ALS/FTLD
por: Imaizumi, Kent, et al.
Publicado: (2022)

Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals
por: Tamaki, Yoshitaka, et al.
Publicado: (2018)

The ALS/FTLD-related RNA-binding proteins TDP-43 and FUS have common downstream RNA targets in cortical neurons()
por: Honda, Daiyu, et al.
Publicado: (2013)

Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations
por: Pottier, Cyril, et al.
Publicado: (2021)

Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD
por: Ward, Michael E., et al.
Publicado: (2014)

Metals in ALS TDP-43 Pathology
por: Koski, Lassi, et al.
Publicado: (2021)

Publisher Correction to: Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies
por: Koga, Shunsuke, et al.
Publicado: (2023)

Spinal cord extracts of amyotrophic lateral sclerosis spread TDP-43 pathology in cerebral organoids
por: Tamaki, Yoshitaka, et al.
Publicado: (2023)

The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
por: Collins, Mahlon, et al.
Publicado: (2012)

Neuronal VCP loss of function recapitulates FTLD-TDP pathology
por: Wani, Abubakar, et al.
Publicado: (2021)

Molecular Neuropathology of TDP-43 Proteinopathies
por: Neumann, Manuela
Publicado: (2009)

Nuclear Expression of TDP-43 Is Linked with Morphology and Ubiquitylation of Cytoplasmic Aggregates in Amyotrophic Lateral Sclerosis
por: Yabata, Hiroyuki, et al.
Publicado: (2023)

FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases
por: Rusina, Robert, et al.
Publicado: (2011)

Which TDP-43 aggregates are toxic in ALS?
por: Valle, Cristiana, et al.
Publicado: (2016)

Regional and hemispheric susceptibility of the temporal lobe to FTLD-TDP type C pathology
por: Borghesani, V., et al.
Publicado: (2020)

Molecular, functional, and pathological aspects of TDP-43 fragmentation
por: Chhangani, Deepak, et al.
Publicado: (2021)

Detection and quantification of novel C‐terminal TDP‐43 fragments in ALS‐TDP
por: Feneberg, Emily, et al.
Publicado: (2021)

Does a loss of TDP-43 function cause neurodegeneration?
por: Xu, Zuo-Shang
Publicado: (2012)

TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
por: Scotter, Emma L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ltgseaaflu37vpod08unj7htnq